Enteral Feeding Formulas Market Size, Share & Trends Analysis Report By Product, By Flow Type, By Stage, By Indication, By End-user, By Sales Channel, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global enteral feeding formulas market size was valued at USD 6.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.5% from 2023 to 2030. A rise in the prevalence of chronic diseases such as cancer, stroke, multiple sclerosis, dementia, chronic liver disease, chronic obstructive pulmonary disease (COPD), and diabetes is projected to drive the demand for products that support patients with oral intake issues.

The rise in preterm births is one of the significant factors boosting the demand for sip feeds to meet the nutritional requirements of newborns. According to the WHO, the rate of preterm birth ranges between 5-18% of babies born across the world. In addition, the continued rise in nutritional and other deficiencies, including severe deficiency of micronutrients, proteins, and other nutrients, especially in infants and pregnant women, is leading to an increase in the demand for enteral feeding formulas.

Sarcopenia, which is a decrease in muscle strength & function, is an aging-related condition, and dietary management in patients suffering from the condition requires enteral foods. According to an article published in BioMed Central in December 2022, the prevalence of sarcopenia was reported to be around 1-29% in older adults and was higher among patients in long-term care. Moreover, the study reported that malnutrition and sarcopenia overlapped in older adults, and patients with a risk of malnutrition were reported to be at high risk of sarcopenia.

Enteral nutrition helps treat and prevent aging-induced sarcopenia. Thus, the rapid rise in the elderly population and increase in the prevalence of age-related chronic diseases & medical conditions are expected to contribute to the growth of the market.Prominent companies such as Nestlé specialize in personalized clinical nutrition products, which include Deplin for depression and Metanx for diabetes.

Deplin is different from nonprescription folic acid, as it contains already-activated folate. It is to be noted that 70% of the patients suffering from depression have a low ability to activate folate, and therefore, the demand for medical foods such as Deplin has increased for various non-metabolizing patients. These factors are likely to drive the demand for clinical nutrition by helping enhance the effectiveness of the treatment and improving the overall quality of medical treatment.

The high prevalence of preterm births, especially in emerging economies such as India and China, is expected to drive market growth. As per the WHO, in 2021, 1 in 10 babies were born preterm, accounting for around 15 million children globally, which is a global concern. Many of these children suffer from lifetime disabilities, hearing & visual impairments, learning disabilities, and others. Thus, the high incidence of preterm births in emerging economies, coupled with improving healthcare infrastructure and growing healthcare expenditure & patient awareness, is expected to be a high-impact rendering driver for the market during the forecast period.

Several studies justify the use of enteral feeds for patients suffering from malnutrition problems that intensified during the pandemic, leading to market growth. For instance, according to an article published in the Journal of the Academy of Nutrition and Dietetics, many patients admitted to the ICU for COVID-19 treatment suffered from acute malnourishment.

COVID-19 Enteral Feeding Market Impact: 8.3% Increase In Revenue Growth from 2019 to 2020

Thus, the usage of enteral feeding formulas is expected to increase in the market. Therefore, stringent regulations, an increasing number of patients developing gastrointestinal problems along with COVID-19, and the growing prevalence of chronic conditions in the geriatric population are anticipated to positively impact the market and boost the adoption of enteral feeding formulas in the coming years.

Product Insights

Based on product, the standard formula segment held the largest market share of 57.0% in 2022. This high share can be attributed to the wide adoption of standard formulas among all types of patients and their associated cost-effectiveness. In addition, the easy availability of polymeric nutritional complete formulas, which are suitable for use in both hospitals and home care settings, is anticipated to accelerate segment growth in the coming years.

The disease-specific formulas segment is expected to grow at the fastest rate due to an increase in the prevalence of several chronic disorders, such as diabetes, cancer, and cardiovascular diseases. These formulas provide nutritional support to individuals suffering from specific diseases that are often characterized by organ dysfunction. These formulations are used for patients suffering from hepatic and pulmonary diseases, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), and diabetes.

Flow Type Insights

The intermittent feeding flow segment dominated the market with a revenue share of 89.2% in 2022. Intermittent tube feeding is useful for patients that need nutrient intake at intervals. It is preferred in cases where a nasogastric feeding tube is being used. In the elderly population, malnutrition and dysphagia are common and can lead to nutritional deficiency, thus increasing the need for enteral feeding to provide essential nutrients. As per the Dysphagia Fact Sheet 2019, around 10% of the acutely hospitalized elderly population and 50-75% of nursing home residents suffered from dysphagia in the UK.

The continuous feeding flow segment is anticipated to advance at the fastest CAGR of 6.9% over the forecast period. It is recommended for critically ill patients suffering from conditions such as respiratory failure, severe burns, and cancer. For instance, according to an article published in MDPI in January 2022, in a controlled trial, the continuous enteral feeding group achieved more than 80% of the target nutrition requirement more frequently than the intermittent enteral feeding group.

Stage Insights

The adult segment dominated the market with a share of 90.4% in 2022. Developing and developed economies are struggling in some or the other form to procure food. Lack of consistent access to food has been termed as “food insecurity” by the USDA. Moreover, the prevalence of malnutrition and undernourishment is rising globally. Depending on the patient condition, nasogastric, gastrostomy, or enterostomy feeding is administered. Hyperemesis gravidarum, characterized by severe nausea and vomiting in pregnant women, leads to dehydration, nutrition deficiency, and fetal morbidity & mortality.

According to an article published in PLOS Global Public Health in November 2022, the prevalence of low birth weight globally is estimated to be around 15% to 20% of total births, accounting for more than 20 million births every year. Furthermore, pediatric patients with dysfunctional or nonfunctional gastrointestinal tracts are unable to ingest nutrients orally and, hence, are administered enteral feeding.

Indication Insights

The other indications segment dominated the enteral feeding formulas market with a revenue share of 37.1% in 2022. Some of the other indications include COPD, respiratory disorders, cystic fibrosis, postoperative stress inflammation, and infections. Due to an increase in the prevalence of various conditions wherein enteral nutrition can be used for the restoration of nutritional balance, the market is anticipated to grow at a significant rate over the forecast period.

According to an article published in the PLOS Global Public Health forum in November 2022, the prevalence of low birth weight globally is estimated to be around 15-20% of the total births, accounting for more than 20 million births every year. Furthermore, pediatric patients with dysfunctional or non-functional gastrointestinal tracts are unable to ingest nutrients orally and, hence, are administered enteral feeding.

Sales Channel Insights

Based on sales channels, the institutional sales segment dominated the market with 51.9% of the revenue share in 2022. Institutions that purchase enteral nutrition products include hospitals, long-term care centers, hospices, and disability facilities. The purchase decision of enteral nutrition formulas is influenced by doctors. Furthermore, the growing number of private and public healthcare institutions and the increasing chronic disease patient population across the globe is impelling the segment growth.

The online sales channel segment is projected to advance at the fastest CAGR over the forecast period. There is a shift in the trend toward direct selling to customers via e-commerce platforms. The preference for online purchase of enteral feeding formulas is rising owing to the convenience offered by this sales channel. Although consumed under medical surveillance, these products are intended for long-term nutrition management, resulting in growing sales through e-commerce.

End-use Insights

With regards to end-use, the home care segment is projected to showcase the fastest CAGR of 5.8% over the projection period. Home enteral nutrition includes different subtypes such as hospices, home health agencies, nursing homes, adult day care centers, and residential care communities. According to data published by the CDC, in 2018, the number of hospices in the U.S. was around 4,700 and the number of patients opting for hospices was 1,426,000. In addition, there were 28,900 residential care communities and around 1.6 million patients were living as residents.

The rising number of hospital-associated cases of malnutrition is a notable indicator of the growing demand for enteral feeding formulas in hospitals. Tube feeding requires proper training & precision and is recommended to be used under proper guidance; hence, many hospitalized patients are recommended enteral feeding to meet the daily requirement of nutrition.

Regional Insights

North America had the largest market share of 28.9% as of 2022. In the U.S., many individuals are suffering from head & neck cancer, which is expected to boost the adoption of these formulas. For instance, according to CDC, in 2019, 47,813 new cases of oral cavities and pharynx cancer were reported in the country. Moreover, the increasing incidence of various chronic disorders such as neurological diseases is anticipated to increase the applications of enteral feeding formulas during the forecast period.

On the other hand, Asia Pacific is anticipated to register the fastest growth rate over the coming years. The growing geriatric population in Japan is likely to drive the demand for enteral feeding formulas in the country over the forecast period. According to World Bank, in 2021, over 30% of the Japanese population was aged 65 & above. According to a UN report, the elderly population will increase twofold from 10% in 2017 to 20% by 2037 in China. Moreover, an increase in the number of hospitalized patients affected by malnutrition in Australia has fueled the growth of the market.

Key Companies & Market Share Insights

The market is characterized by the presence of leading players with strong product portfolios, global presence, and financial performance. For instance, Abbott, headquartered in the U.S., markets and sells its products in more than 150 countries across the globe. In January 2023, Nestlé announced its plans for an investment of USD 43 million to expand its manufacturing facility in Eau Claire, Wisconsin in the U.S. Some key players operating in the global enteral feeding formulas market include:

• Abbott

• Danone S.A

• Fresenius Kabi AG

• Nestlé

• VICTUS

• Primus Pharmaceuticals, Inc.

• Meiji Holdings. Co., Ltd.

• Mead Johnson & Company, LLC

Enteral Feeding Formulas Market Report Scope

Global Enteral Feeding Formulas Market Report Segmentation

This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global enteral feeding formulas market report based on product, flow type, stage, indication, end-use, sales channel, and region:

• Product Outlook (Revenue, USD Billion, 2018 - 2030)

  • Standard Formula

  • Disease-specific Formulas

• Flow Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Intermittent Feeding Flow

  • Continuous Feeding Flow

• Stage Outlook (Revenue, USD Billion, 2018 - 2030)

  • Adults 

  • Pediatrics

• Indication Outlook (Revenue, USD Billion, 2018 - 2030)

  • Alzheimer’s

  • Nutrition Deficiency

  • Cancer Care

  • Diabetes

  • Chronic Kidney Diseases

  • Orphan Diseases

  • Dysphagia

  • Pain Management

  • Malabsorption/GI Disorder/Diarrhea

  • Others

• End-use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Hospitals

    • Cardiology

    • Neurology

    • Critical Care (ICU)

    • Oncology

    • Others

  • Home Care

• Sales Channel Outlook (Revenue, USD Billion, 2018 - 2030)

  • Online Sales

  • Retail Sales

  • Institutional Sales

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Spain `          

    • Italy

    • Russia

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait